Abstract
Rationale
Gamma-hydroxybutyrate acid (GHB), a GABAB receptor agonist approved for treatment of narcolepsy, impairs driving ability, but little is known about doses and plasma concentrations associated with impairment and time course of recovery.
Objective
To assess effects of oral GHB (Xyrem®) upon driving as measured by a driving simulator, and to determine plasma concentrations associated with impairment and the time course of recovery.
Methods
Randomized, double-blind, two-arm crossover study, during which 16 participants received GHB 50 mg/kg orally or placebo. GHB blood samples were collected prior to and at 1, 3, and 6 h post dosing. Driving simulator sessions occurred immediately after blood sampling.
Results
Plasma GHB was not detectable at baseline or 6 h post dosing. Median GHB concentrations at 1 and 3 h were 83.1 mg/L (range 54–110) and 24.4 mg/L (range 7.2–49.7), respectively. Compared to placebo, at 1 h post GHB dosing, significant differences were seen for the life-threatening outcome collisions (p < 0.001) and off-road accidents (p = 0.018). Although driving was not faster, there was significantly more weaving and erratic driving with GHB as measured by speed deviation (p = 0.002) and lane position deviation (p = 0.004). No significant impairment regarding driving outcomes was found in the GHB group at 3 and 6 h post dose.
Conclusion
GHB in doses used to treat narcolepsy resulted in severe driving impairment at 1 h post dosing. After 3 to 6 h, there was full recovery indicating that safe driving is expected the next morning after bedtime therapeutic GHB use in the absence of other substances.
Similar content being viewed by others
References
Abanades S, Farré M, Barral D, Torrens M, Closas N, Langohr K, Pastor A, de la Torre R (2007) Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol 27(6):625–638
Akinwuntan AE, De Weerdt W, Feys H, Pauwels J, Baten G, Arno P, Kiekens C (2005) Effect of simulator training on driving after stroke: a randomized controlled trial. Neurology 65(6):843–850
Al-Samarraie MS, Karinen R, Mørland J, Stokke Opdal M (2010) Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway. Eur J Clin Pharmacol 66(10):987–998
Anderson IB, Kim SY, Dyer JE, Burkhardt CB, Iknoian JC, Walsh MJ, Blanc PD (2006) Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Ann Emerg Med 47(2):177–183
Arnedt JT, Owens J, Crouch M, Stahl J, Carskadon MA (2005) Neurobehavioral performance of residents after heavy night call vs after alcohol ingestion. JAMA 294(9):1025–1033
Bania TC, Ashar T, Press G, Carey PM (2003) Gamma-hydroxybutyric acid tolerance and withdrawal in a rat model. Acad Emerg Med 10(7):697–704
Borgen LA, Cook HN, Hornfeldt CS, Fuller DE (2002) Sodium oxybate (GHB) for treatment of cataplexy. Pharmacotherapy 22(6):798–799 discussion 799
Borgen LA, Okerholm RA, Lai A, Scharf MB (2004) The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J Clin Pharmacol 44(3):253–257
Bosch OG, Eisenegger C, Gertsch J, von Rotz R, Dornbierer D, Gachet MS, Heinrichs M, Wetter TC, Seifritz E, Quednow BB (2015) Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone. Psychoneuroendocrinology 62:1–10
Bosman IJ, Lusthof KJ (2003) Forensic cases involving the use of GHB in The Netherlands. Forensic Sci Int 133(1–2):17–21
Brenneisen R, Elsohly MA, Murphy TP, Passarelli J, Russmann S, Salamone SJ, Watson DE (2004) Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 28(8):625–630
Burch HJ, Clarke EJ, Hubbard AM, Scott-Ham M (2013) Concentrations of drugs determined in blood samples collected from suspected drugged drivers in England and Wales. J Forensic Legal Med 20(4):278–289
Busardò FP, Jones AW (2015) GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol 13(1):47–70
Carter LP, Richards BD, Mintzer MZ, Griffiths RR (2006) Relative abuse liability of GHB in humans: a comparison of psychomotor,subjective, and cognitive effects of supratherapeutic doses of triazolam,pentobarbital, and GHB. Neuropsychopharmacology 31(11):2537–2551
Carter LP, Griffiths RR, Mintzer MZ (2009) Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology 206(1):141–154
Centola C, Giorgetti A, Zaami S, Giorgetti R (2018) Effects of GHB on psychomotor and driving performance. Curr Drug Metab. https://doi.org/10.2174/1389200219666180124113802
Couper FJ, Logan BK (2001) GHB and driving impairment. J Forensic Sci 46(4):919–923
Couper FJ, Logan BK (2004) Addicted to driving under the influence—a GHB/GBL case report. J Anal Toxicol 28(6):512–515
Couper FJ, Marinetti LJ (2002) γ-Hydroxybutyrate (GHB)—effects on human performance and behavior. Forensic Sci Rev 14(1–2):101–121
Dempsey D, Murphy N, Benowitz NL, Wiegand T, Wu L, Haller CA (2007) Respiratory effects of gamma-hydroxybutyrate (GHB) and ethanol. Clin Pharm Ther 81(Supplement 1):S51
Drasbek KR, Christensen J, Jensen K (2006) Gamma-hydroxybutyrate—a drug of abuse. Acta Neurol Scand 114(3):145–156
Dresen S, Kempf J, Weinmann W (2007) Prevalence of gamma-hydroxybutyrate (GHB) in serum samples of amphetamine, metamphetamine and ecstasy impaired drivers. Forensic Sci Int 173(2–3):112–116
ElSohly MA, Salamone SJ (1999) Prevalence of drugs used in cases of alleged sexual assault. J Anal Toxicol 23(3):141–146
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2008) GHB and its precursor GBL: an emerging trend case study. http://wwwemcddaeuropaeu/system/files/publications/505/TP_GHB_and_GBL_107300pdf Accessed June 2018
Ferrara SD, Giorgetti R, Zancaner S, Orlando R, Tagliabracci A, Cavarzeran F, Palatini P (1999) Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol 54(11):821–827
Fritz CO, Morris PE, Richler JJ (2012) Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 141(1):2–18
Frucht SJ, Houghton WC, Bordelon Y, Greene PE, Louis ED (2005) A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 65(12):1967–1969
Fuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF (2004) The Xyrem risk management program. Drug Saf 27(5):293–306
Gonzalez A, Nutt DJ (2005) Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 19(2):195–204
Itzhak Y, Ali SF (2002) Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB. Ann N Y Acad Sci 965:451–460
Johnson MW, Griffiths RR (2013) Comparative abuse liability of GHB and ethanol in humans. Exp Clin Psychopharmacol 21(2):112–123
Jones AW, Holmgren A, Kugelberg FC (2007) Gamma-hydroxybutyrate concentrations in the blood of impaired drivers, users of illicit drugs, and medical examiner cases. J Anal Toxicol 31(9):566–572
Keating GM (2014) Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. Clin Drug Investig 34(1):63–80
Lenne MG, Dietze P, Rumbold GR, Redman JR, Triggs TJ (2003) The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving. Drug Alcohol Depend 72(3):271–278
Liakoni E, Walther F, Nickel CH, Liechti ME (2016) Presentations to an urban emergency department in Switzerland due to acute γ-hydroxybutyrate toxicity. Scand J Trauma Resusc Emerg Med 24(1):107
Liechti ME, Quednow BB, Liakoni E, Dornbierer D, von Rotz R, Gachet MS, Gertsch J, Seifritz E, Bosch OG (2016) Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects. Br J Clin Pharmacol 81(5):980–988
Mattila MJ, Palva E, Seppälä T, Ostrovskaya RU (1978) Actions and interactions with alcohol of drugs on psychomotor skills: comparison of diazepam and gamma-hydroxybutyric acid. Arch Int Pharmacodyn Ther 234(2):236–246
McElroy SL, Guerdjikova AI, Winstanley EL, O'Melia AM, Mori N, Jr Keck PE, Hudson JI (2011) Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study. Int J Eat Disord 44(3):262–268
Miró Ò, Galicia M, Dargan P, Dines AM, Giraudon I, Heyerdahl F, Hovda KE, Yates C, Wood DM, Euro-DEN Research Group (2017) Intoxication by gamma hydroxybutyrate and related analogues: clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse. Toxicol Lett 277:84–91
Moskowitz H, Burns M, Fiorentino D, Smiley A, Zador P (2000) Driving characteristics and impairment at various BACs, DOT HS 809 075 (P. J. Tremont, ed.), US Department of Transportation, National Highway Traffice Safety Administration, pp. 1–60. www.nhtsa.dot.gov/people/injury/research/pub/impaired_driving/BAC/impairment.pdf Accessed March 2018
National Drug Intelligence Center (2002) Information bulletin: GHB analogs GBL, BD, GHV and GVL, National Drug Intelligence Center https://wwwjusticegov/archive/ndic/pubs1/1621/1621thtm Accessed March 2018
Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J (2010) Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol 21(4):332–342
Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, Gallimberti L, Gessa GL, Ferrara SD (1993) Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 45(4):353–356
Pan YM, Gill GN, Tilson CS, Wall WH, McCurdy HH (2001) Improved procedure for the analysis of gamma-hydroxybutyrate and ethylene glycol in whole blood. J Anal Toxicol 25(5):328–332
Partinen M, Hirvonen K, Hublin C, Halavaara M, Hiltunen H (2003) Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med 4(6):553–561
Product Information: Xyrem® (2012) Oral solution, sodium oxybate oral solution. Jazz Pharmaceuticals (per FDA), Palo Alto
Rumbach AF, Blitzer A, Frucht SJ, Simonyan K (2017) An open-label study of sodium oxybate in spasmodic dysphonia. Laryngoscope 127(6):1402–1407
Russell IJ, Perkins AT, Michalek JE (2009) Oxybate SXB-26 fibromyalgia syndrome. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 60(1):299–309
Scharf MB, Lai AA, Branigan B, Stover R, Berkowitz DB (1998) Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 21(5):507–514
Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B (2012) The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 50(6):458–470
Schröck A, Hari Y, König S, Auwärter V, Schürch S, Weinmann W (2014) Pharmacokinetics of GHB and detection window in serum and urine after single uptake of a low dose of GBL—an experiment with two volunteers. Drug Test Anal 6(4):363–366
Snead OC III, Gibson KM (2005) Gamma-hydroxybutyric acid. N Engl J Med 352(26):2721–2732
Staner L, Ertle S, Boeijinga P, Rinaudo G, Arnal MA, Muzet A, Luthringer R (2005) Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology 181(4):790–798
Stephens BG, Baselt RC (1994) Driving under the influence of GHB? J Anal Toxicol 18(6):357–358
Thai D, Dyer JE, Benowitz NL, Haller CA (2006) Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol 26(5):524–529
Thai D, Dyer JE, Jacob P, Haller CA (2007) Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther 81(2):178–184
Turkington PM, Sircar M, Allgar V, Elliott MW (2001) Relationship between obstructive sleep apnoea, driving simulator performance, and risk of road traffic accidents. Thorax 56(10):800–805
Wallace DM, Maze T, Shafazand S (2011) Sodium oxybate-induced sleep driving and sleep-related eating disorder. J Clin Sleep Med 7(3):310–311
Weiler JM, Bloomfield JR, Woodworth GG, Grant AR, Layton TA, Brown TL, McKenzie DR, Baker TW, Watson GS (2000) Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 132(5):354–363
Acknowledgments
We thank the nurses and staff of the Clinical Research Center of San Francisco General Hospital for their help, and Newton Addo for statistical and technical support.
Funding
This study is supported by the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research, Grant Numbers MO1RR00083-44 and UL1 RR024131-01, NIDA DA14935, and DA12393.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was performed with informed consent and with the approval of the Committee on Human Research of the University of California, San Francisco.
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
ESM 1
(DOCX 15.9 kb)
Rights and permissions
About this article
Cite this article
Liakoni, E., Dempsey, D.A., Meyers, M. et al. Effect of γ-hydroxybutyrate (GHB) on driving as measured by a driving simulator. Psychopharmacology 235, 3223–3232 (2018). https://doi.org/10.1007/s00213-018-5025-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-018-5025-2